Onconetix, Inc. - BWV STOCK NEWS

Blue Water Vaccines (BWV) has appointed Simon Tarsh, a veteran financial consultant with over 40 years in the industry, to its board of directors during the recent annual meeting. Tarsh's extensive experience includes senior roles at Deloitte Consulting, where he specialized in operational transformation and global financial practices. His insights are expected to enhance BWV's vaccine pipeline development. BWV is focused on innovative vaccines for significant global health issues, including a universal flu vaccine and a candidate for acute otitis media in children.

Blue Water Vaccines (BWV) announced plans to develop a novel monkeypox vaccine utilizing its norovirus shell and protrusion virus-like particle (VLP) platform. This platform is already in use for vaccine candidates, including those for influenza and malaria. With rising monkeypox cases globally, BWV aims to leverage its platform for a potential vaccine, amid limited availability of existing vaccines in the U.S. The company has entered a global licensing agreement with Cincinnati Children’s for this development, showcasing its commitment to addressing significant health challenges.

Blue Water Vaccines (BWV) reported financial results for Q2 2022, highlighting a cash position of $22.2 million as of June 30, 2022, up from $18.6 million in Q1 2022. The company raised approximately $6.9 million and $8.8 million through private placements in April and August 2022, respectively. R&D expenses increased to $1.3 million, while G&A expenses rose to $3.0 million. The net loss was approximately $4.3 million, significantly higher than $0.8 million in Q2 2021. BWV is developing various vaccine candidates.

Blue Water Vaccines (BWV) has completed a private placement of 3,683,280 shares at a price of $2.715 per share, raising approximately $10 million. This capital will support the research and development of their vaccine pipeline and general corporate purposes. The company now has a cash position of around $30.3 million, including the placement proceeds. Additionally, BWV will issue investment options to purchase up to 4,972,428 shares. Investors agreed to cancel previously issued options for 1,180,812 shares. The securities from this offering are not registered under the Securities Act.

Blue Water Vaccines (BWV) has announced a private placement of 3,683,280 shares of common stock and unregistered preferred investment options to healthcare-focused institutional investors. The shares are priced at $2.715 each, with a gross proceeds estimate of approximately $10 million. BWV plans to use the net proceeds for R&D, working capital, and corporate purposes, increasing its cash position to about $30.3 million. The offering, facilitated by H.C. Wainwright & Co., is set to close around August 11, 2022, pending customary conditions.

Blue Water Vaccines (BWV) has entered into a Sponsored Research Agreement with Cincinnati Children’s Hospital to enhance its norovirus vaccine platform, initially developed for gastroenteritis. This partnership aims to explore vaccine potential against influenza and Alzheimer's disease. The SRA will facilitate research on integrating innovative epitopes from Oxford University into their vaccine platform. BWV's technology is poised to tackle significant global health issues, and recent studies indicate the promising versatility of their vaccine candidates. This collaboration signifies a strategic investment in public health initiatives.

Oragenics, Inc. (NYSE American: OGEN) has appointed Kimberly M. Murphy as President and CEO effective June 23, 2022. Murphy, a seasoned vaccine industry leader with over 25 years of experience, has previously held significant roles at companies like Merck and GSK. Her appointment is expected to enhance Oragenics' strategic vision and accelerate growth, particularly in their ongoing vaccine development efforts against infectious diseases, including COVID-19. As a board member since 2020, her insights have already contributed to the company’s strategies.

Blue Water Vaccines (BWV) announced that Joseph Hernandez, Chairman and CEO, will present at the JMP Securities Life Science Conference on June 15, 2022, at 11:30 AM EDT. The presentation will provide an overview of BWV's vaccine candidate pipeline and recent developments.

Hernandez expressed excitement to share the company's mission and progress in vaccine development, highlighting key updates in financing and collaborations. BWV is focused on developing vaccines for various infectious diseases, including a universal flu vaccine and a pneumococcus vaccine aimed at preventing ear infections in children.

Blue Water Vaccines (BWV) announced an 18-month extension of its Sponsored Research Agreement with The University of Oxford, focusing on the development of its universal influenza vaccine candidate, BWV-101. This amendment builds on an original three-year agreement initiated in December 2019. Oxford's recent research identified new epitopes for H3 and influenza B, advancing the vaccine's effectiveness. The global burden of influenza includes over 1 billion infections annually, prompting the necessity for a universal vaccine.